10-Q

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________________to__________________________

Commission File Number: 000-54582

United Cannabis Corporation

(Exact name of Registrant as specified in its charter)

Colorado	26-1391338
(State or other jurisdiction of incorporation or formation)	(I.R.S. employer identification number)

Suite 200-883

9249 South Broadway

Highlands Ranch, CO  80129

 (Address of principal executive offices - Zip Code)

(303) 904-9296

(Registrant’s telephone number, including area code)

N/A

 (Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ  No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨	Accelerated filer  ¨
Non-accelerated filer    ¨ (Do not check if a smaller reporting company)	Smaller reporting company  þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No þ

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

On November 19, 2014, there were 43,850,000 shares of the issuer’s common stock were outstanding.

UNITED CANNABIS CORPORATION

INDEX

		Page No.
PART I	FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS:	1
	Condensed Balance Sheets — September 30, 2014 (Unaudited) and December 31, 2013	1
	Condensed Statements of Operations (Unaudited) — Three and nine months ended September 30, 2014 and 2013	2
	Condensed Statements of Cash Flows (Unaudited) — Three and nine months ended September 30, 2014 and 2013	3
	Notes to Condensed Financial Statements (Unaudited)	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4.	CONTROLS AND PROCEDURES	23
PART II	OTHER INFORMATION
ITEM 1	LEGAL PROCEEDINGS	24
ITEM 1A	RISK FACTORS	24
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	24
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	24
ITEM 4	MINE SAFETY DISCLOSURES	24
ITEM 5	OTHER INFORMATION	24
ITEM 6	EXHIBITS	24
	SIGNATURES	25

PART 1.  FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

UNITED CANNABIS CORPORATION

CONDENSED BALANCE SHEETS

	September 30, 2014			December 31, 2013
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	189,357		$	32,414
Accounts receivable		16,113			—
Investments in non-marketable equity securities		300,000			—
Due from related party		—			8,862
Prepaid expenses and other assets		188,450			—
Assets of discontinued operations		—			17,616
Total current assets		693,920			58,892
Investments in non-marketable equity securities		593,750			—
Equity method investments		282,000			—
Notes and interest receivable		1,263,150			—
Total assets	$	2,832,820		$	58,892
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	38,571		$	—
Accrued expenses		130,452			—
Derivative liability		165,488			—
Current portion of deferred revenue		444,000			—
Note payable		175,000			—
Current portion of convertible note payable, net		47,083			—
Convertible note payable, related party		—			50,000
Total current liabilities		1,000,594			50,000
Long term liabilities:
Deferred revenue, net of current portion		518,750			—
Convertible note payable, net and net of current portion		715,918			—
Total liabilities		2,235,262			50,000
Stockholders' equity:
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding		—			—
Common stock, no par value; 100,000,000 shares authorized; 43,800,000 (unaudited) and 6,020,000* issued and outstanding, respectively		2,006,019			165,495
Common stock not yet issued, 40,000 shares		88,000			—
Accumulated deficit		(1,496,461	)		(156,603	)
Total stockholders' equity		597,558			8,892
Total liabilities and stockholders' equity	$	2,832,820		$	58,892

———————

*

The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

See accompanying notes to condensed unaudited financial statements.

1

UNITED CANNABIS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Revenue	$	91,113		$	—		$	91,113		$	—
Cost of goods sold		2,136			—			2,136			—
Gross profit		88,977			—			88,977			—
Operating expenses:
Sales and marketing		20,205			—			94,363			—
Research and development		94,751			—			170,805			—
General and administrative		522,421			21,694			946,562			32,471
Total operating expenses		637,377			21,694			1,211,730			32,471
Loss from operations		(548,400	)		(21,694	)		(1,122,753	)		(32,471	)
Other income (expense):
Interest income		13,154			—			13,179			—
Loss on derivative liability		(1,942	)		—			(1,942	)		—
Interest expense		(67,488	)		—			(67,488	)		—
Loss on origination of derivative liability		(12,810	)		—			(12,810	)		—
Amortization of debt discount		(89,152	)		—			(89,152	)		—
Total other income (expense)		(158,238	)		—			(158,213	)		—
Loss from continuing operations		(706,638	)		(21,694	)		(1,280,966	)		(32,471	)
Net income (loss) from discontinued operations		—			(5,578	)		(58,892	)		14,244
Net loss	$	(706,638	)	$	(27,272	)	$	(1,339,858	)	$	(18,227	)
Net income (loss) per share:
Net loss per share from continuing operations:
Basic and diluted	$	(0.02	)	$	(0.00	)*	$	(0.03	)	$	(0.00	)*
Net income (loss) per share from discontinued operations:
Basic and diluted	$	n/	a	$	(0.00	)*	$	(0.00	)*	$	0.00	*
Net income (loss) per common share:
Basic and diluted	$	(0.02	)	$	(0.00	)*	$	(0.03	)	$	(0.00	)*
Basic and diluted weighted-average common shares outstanding:		43,656,304			6,020,000	**		43,389,744			6,020,000	**

———————

*

Denotes income or loss of less than $0.01 per share.

**

The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

See accompanying notes to condensed unaudited financial statements.

2

UNITED CANNABIS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended September 30,
	2014			2013
Operating activities:
Net loss	$	(1,339,858	)	$	(18,227	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation - assets of discontinued operations		—			20,299
Loss on sale of assets of discontinued operations		15,704			—
Management fees and reimbursement of expenses, related parties, net, of discontinued operations		—			(38,389	)
Amortization of debt discount		89,152			—
Non-cash interest expense		11,609			—
Convertible note payable issued for debt issuance costs		32,500			—
Loss on origination of derivative liability		12,810			—
Shares issued for services		34,000			—
Value of non-marketable equity securities recognized as revenue		(75,000	)		—
Loss on revaluation of derivative liability		1,942			—
Changes in operating assets and liabilities:
Accounts receivable		(16,113	)		—
Interest receivable		(13,150	)		—
Due from related party		10,774			—
Inventory		—			(3,026	)
Due to related party		—			5,445
Prepaid expenses		(26,450	)		—
Accounts payable and accrued expenses		169,023			10,838
Net cash provided by (used in) operating activities		(1,093,057	)		(23,060	)
Investing activities:
Equity method investments		(50,000	)		—
Equipment purchases related to discontinued operations		—			(18,215	)
Net cash provided by (used in) investing activities		(50,000	)		(18,215	)
Financing activities:
Net proceeds from issuance of convertible debt and warrants		225,000			—
Proceeds from issuance of note payable		175,000			—
Repayment of notes payable, related party		—			(50,000	)
Proceeds from convertible note payable, related party					50,000
Proceeds from issuance of common shares		900,000			—
Net cash provided by (used in) financing activities		1,300,000			—
Net increase (decrease) in cash		156,943			(41,275	)
Cash, beginning of period		32,414			76,445
Cash, end of period	$	189,357		$	35,170

See accompanying notes to condensed unaudited financial statements.

3

UNITED CANNABIS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended September 30,
	2014		2013
Supplemental schedule of cash flow information:
Cash paid for interest	$	—	$	—
Cash paid for income taxes	$	—	$	—
Supplemental disclosure of non-cash investing and financing activities:
Investment in non-marketable equity securities received as consideration for deferred services	$	893,750	$	—
Investment in equity method investments received as consideration for deferred services	$	144,000	$	—
Investment in equity method investments received for commitment to issue common stock	$	88,000	$	—
Issuance of common stock for prepaid professional fees	$	162,000	$	—
Acquisition of notes receivable funded by convertible note payable	$	1,250,000	$	—
Issuance of convertible note payable for debt issuance costs	$	32,500	$	—
Warrants issued for debt discount	$	694,525	$	—
Debt conversion feature issued for debt discount	$	151,937	$	—
Debt conversion feature issued for interest payable discount	$	11,609	$	—
Conversion of note payable, related party, into common stock	$	50,000	$	—

See accompanying notes to condensed unaudited financial statements.

4

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS

Current Operations and Background – United Cannabis Corporation ("we", "our", "us" or "UCC") a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. UCC was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCC, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.

On March 26, 2014, we entered into a License Agreement with Earnest Blackmon ("Blackmon"), Tony Verzura ("Verzura") and Chad Ruby ("Ruby") pursuant to which Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.

In connection with this transaction:

· Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid (cannabidol or "CBD") therapy program called "A.C.T. Now", security, regulatory compliance, and any other methods and processes which relate to the cannabis industry.

· The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.

· Blackmon, Verzura and Ruby were appointed to our board of directors effective April 8, 2014.

· Blackmon was elected as our President, Ruby was elected as Chief Operating Officer and Verzura was elected as Vice President. On June 24, 2014, Blackmon was elected as our CEO and CFO.

· A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.

As a result of this transaction our business plan has changed. We are beginning to create partnerships with businessmen, entrepreneurs, scientists and others, both domestically and internationally, for the purpose of developing cannabis-based products worldwide.

For example, we are starting to enter into licensing and consulting agreements with partners who desire to license our entire turnkey seed-to-sale business model in jurisdictions where it is legal to do so, and we plan to typically receive a percentage of their gross revenues as our fee. In addition to licensing our intellectual property, we are offering consulting services on the design and buildout of cultivation facilities; we offer training and staffing services; and we will assist our partners in finding the right locations for cultivation facilities. We provide our partners access to our genetic catalogue which includes over 15 CBD strains, over 150 THC strains and over 30 Cannabis Cup winners.

We also provide our partners access to our full range of extracted/infused medical products. Our plan includes licensing our intellectual property for whole plant activated oils, smokable concentrates, infused products, topical lotions, pills, sublingual transdermal patches and our partners will have access to future technology and products that we develop.

Our goals are to establish strong cultivation positions through our local partners in markets where it is legal and use these revenues to develop new cannabinoid based drugs for clinical FDA approval patents.

5

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.

Government Regulation - Marijuana is a Schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.

As of November 19, 2014, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado, Washington, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana.   However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously.  Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us.  

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2014 and 2013, are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.

Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of the notes payable and notes receivable at September 30, 2014, approximate their respective fair values based on our incremental borrowing rates.

6

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2014 and December 31, 2013.

Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.

We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer’s financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of September 30, 2014 and December 31, 2013.

Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other assets.

Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.

Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.

Equity Method Investments – Our investments in entities representing ownership of at least 15% but less than 50%, where we exercise significant influence, are accounted for under the equity method.

Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.

Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Advertising Costs - All advertising costs are expensed as incurred.

Research and Development Expense - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.

Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

7

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders’ equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.

Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible notes		337,569		—		337,569		—
Warrants to purchase common stock		997,692		—		3,997,692		—

Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.

The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.

Percentage of Revenue during the Period Ended

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2014			2013		2014			2013
Customer A		82	%		—		82	%		—
Customer B		10	%		—		10	%		—

Percentage of Accounts Receivable during the Period Ended

	September 30, 2014			December 31, 2013
Customer B		43	%		—
Customer C		57	%		—

8

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

NOTE 3 – GOING CONCERN

Our condensed financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2014, we incurred losses of $1,339,858 and used cash of $1,093,057 in our operating activities. As at September 30, 2014, we had a working capital deficit of $306,674 and an accumulated deficit of $1,496,461.  Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES

On May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. (“WMD”), a Canadian private company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represent a 4.29% equity investment in WMD and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at the estimated cost, based on our estimate of the fair value of the securities we received on the date of the transaction.

The warrants entitle us to purchase WMD shares for CDN $0.50 each for a period of nine months from the date the warrant was issued. In addition, we are required to exercise all of these warrants if the holders of our Series A Warrants (see Note 14 below) exercise a minimum of 800,000 of our Series A Warrants prior to the expiration of the WMD warrants.

The WMD common shares were recorded at $0.50 per share based on WMD’s most recent sale of their common shares prior to the date of the transaction (CDN $0.50).

The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the nine months ended September 30, 2014:

Risk free interest rate	0.60	%
Expected term (years)	0.5
Expected volatility	70	%
Expected dividends	0	%

The $300,000 fair value assigned as the cost to the WMD warrants has been classified as a current asset as the warrants expire after nine months, while the $593,750 assigned to the cost of the WMD common shares has been classified as a long term asset as these shares do not expire.

NOTE 5 – PREPAID EXPENSES AND OTHER ASSETS

 Prepaid expenses and other assets consist of:

	September 30, 2014		December 31, 2013
Prepaid investor relations services	$	162,000	$	—
Prepaid accounting fees		550		—
Interest receivable		25,900		—
	$	188,450	$	—

9

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 6 – EQUIPMENT

Our equipment consists of the following at:

	September 30, 2014		December 31, 2013
Equipment	$	—	$	131,584
Less accumulated depreciation		—		(113,968	)
	$	—	$	17,616

NOTE 7 – EQUITY METHOD INVESTMENTS

Our equity method investments consist of:

	September 30, 2014		December 31, 2013
Lone Mountain Partners, LLC – 25% interest	$	50,000	$	—
Om of Medicine, LLC – 15% interest		45,000		—
OM of Illinois, LLC – 33% interest		99,000		—
Cannibinoid Research & Development Company Limited – 50%		88,000		—
Total equity method investments	$	282,000	$	—

On August 14, 2014, we acquired a 25% membership interest in Lone Mountain Partners, LLC, (“Lone Mountain”) for $50,000 and a commitment to provide future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Nevada and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of Lone Mountain. As of September 30, 2014, Lone Mountain did not have any operations or operating activities. We accounted for the $50,000 cash contribution as an equity method investment on our condensed balance sheet.

On August 15, 2014, and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC (together the “Oms”), respectively, in return for a commitment to provide $144,000 of future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Illinois and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of the Oms. As of September 30, 2014, the Oms did not have any operations or operating activities. We accounted for this $144,000 commitment to provide services as deferred revenue in our condensed statements of operations and included this amount in equity method investments on our condensed balance sheets.

On August 15, 2014, we acquired a 50% interest in Cannibinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day’s closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as our intellectual property in the operations of CRD. As of September 30, 2014, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our condensed balance sheet. As we have not yet issued the 40,000 shares, the $88,000 is classified as common stock not yet issued on our condensed balance sheets.

10

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 8 – NOTES AND INTEREST RECEIVABLE

Notes Receivable

On August 13, 2014, in conjunction with the $1,657,500 Typenex Co-Investment, LLC (“Typenex”) convertible promissory note more fully described in Note 12 below, we received five, unsecured, $250,000 Investor Notes bearing interest at 8% per annum, totaling $1,250,000 that mature with respect to principal and interest on September 13, 2016. The Investor Notes can be prepaid at any time, without penalty, by Typenex and Typenex has certain rights to offset the amounts owed to us by amounts we owe to them in accordance with the terms of the Investor Notes. We have the right to call the Investor Notes if the share price of our common stock (as further defined in the Investor Notes terms and conditions) exceeds $6.00 per share for 20 consecutive trading days.

Our intention in entering into this arrangement with Typenex is that the Investor Notes will provide us with a mechanism to obtain additional cash funding. Upon our request and with Typenex’s consent, we can redeem individual Investor Notes for cash before meeting the price threshold of $6.00 per share for 20 consecutive days at which point we have the right to demand repayment of these Investor Notes from Typenex without requiring their consent.

During the three and nine months ended September 30, 2014, we recognized $13,150 of interest income applicable to these Investor Notes and this amount is included in notes and interest receivable on our condensed balance sheets.

NOTE 9 – FAIR VALUE MEASUREMENTS

We have adopted the guidance of ASC 820, Fair Value Measurement, which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The following table provides our liabilities carried at fair value measured on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Derivative liability	$	—	$	—	$	165,488	$	165,488

We did not have any liabilities carried at fair value measured on a recurring basis as of December 31, 2013.

We value our derivative instruments related to embedded conversion features from the initial borrowing of $282,500 under the Typenex convertible note payable (see Note 12 below) and accrued interest of $21,312 thereon in accordance with the Level 3 guidelines. For the nine month period ended September 30, 2014, the following table reconciles the beginning and ending balances for financial instruments that are carried at fair value measured on a recurring basis:

Derivative liability as of December 31, 2013	$	—
Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
Additions to derivative liability for interest payable conversion feature recorded as interest expense		11,609
Loss on revaluation of derivative liability at period end		1,942
Derivative liability as of September 30, 2014	$	165,488

11

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

The fair values of embedded conversion features issued with our convertible debt and accrued interest payable were estimated using the Black-Scholes option pricing model. The key inputs to this valuation model during the nine months ended September 30, 2014, were as follows:

Risk-free interest rate	0.43% – 0.58%
Dividend yield	—
Volatility	146% – 157%
Expected life in years	1.96 – 2.09
Exercise price	$3.00

The following tabular presentation reflects the components of derivative financial instruments on our condensed balance sheets at September 30, 2014 and December 31, 2013:

	September 30, 2014		December 31, 2013
Derivative Liabilities:
Embedded derivative liability in convertible debt	$	153,879	$	—
Embedded derivative liability in interest payable		11,609		—
Total derivative liability	$	165,488	$	—

NOTE 10 – DEFERRED REVENUE

Our deferred revenue consists of:

	September 30, 2014			December 31, 2013
Deferred revenue – WeedMD	$	818,750		$	—
Deferred revenue - Om of Medicine, LLC		45,000			—
Deferred revenue - OM of Illinois, LLC		99,000			—
Less – current portion		(444,000	)		—
Total equity method investments	$	518,750		$	—

As described in Note 4 above, on May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and, based on discussions with WMD, we expect to deliver consulting services and use of our intellectual property to WMD on a consistent monthly basis during a three year period beginning June 1, 2014. Accordingly, we began recognizing $25,000 of deferred revenue per month totaling $75,000 during the three and nine months ending September 30, 2014. At September 30, 2014, we expect to recognize $300,000 of the $818,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $300,000 as a current liability on our condensed balance sheets.

As described in Note 7 above, on August 15, 2014 and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC, respectively, in return for a commitment to provide $144,000 of future services to these entities. As of September 30, 2014, the Oms did not have any operations or operating activities; however, we expect to satisfy our future service obligations during the next twelve months and accordingly, we have classified the $144,000 as a current liability in our condensed balance sheets.

NOTE 11 – NOTES PAYABLE 

On July 7, 2014, we issued a $175,000, unsecured, demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. Interest expense during the three and nine months ending September 30, 2014, was $2,067 and accrued interest payable in that amount is included in accrued expenses on our condensed balance sheets.

12

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 12 – CONVERTIBLE NOTE PAYABLE

Our convertible note payable consists of the following:

	September 30, 2014			December 31, 2013
Convertible note payable-Typenex	$	1,657,500		$	—
Less – current portion		(282,500	)		—
Convertible note payable-noncurrent		1,375,000			—
Less – unamortized discount		(659,082	)		—
Convertible note payable-noncurrent, net	$	715,918		$	—
Convertible note payable-current portion	$	282,500		$	—
Less – unamortized discount		(235,417	)		—
Convertible notes payable-current portion, net	$	47,083		$	—

On August 13, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of a 10% convertible promissory note (the “Note”) in the principal amount of $1,657,500 (the “Closing Amount”) convertible into shares of our common stock. The Note has an original issue discount (“OID”) of $150,000. Typenex retained $7,500 of the Closing Amount for due diligence and legal bills related to the transaction and paid $25,000 on our behalf to a third party for brokerage fees (together, the “Fees”). The financing closed on August 13, 2014 (the “Closing Date”). 

In addition, we issued to Typenex warrants (the “Warrants”) to purchase 997,692 shares of our common stock, subject to adjustment in the event of a cashless exercise, as defined in the Warrant. Warrants for 170,044 shares were immediately exercisable with the remainder only becoming exercisable, in five tranches, if and when the Investor Notes (see Note 8 above) are paid. The Warrants are exercisable at $3.00 per share (the “Exercise Price”) for a period of three years on a cash or cashless basis. If we, at any time while the Warrants are outstanding, sell or issue our common stock or securities convertible into or exercisable for shares of our common stock, including common stock issued under the Note, at an effective price per share less than the Exercise Price, then, subject to a few exceptions set forth in the Warrant, the Exercise Price will be reduced to such lower price provided that the number of shares of common stock issuable under the Warrant may not exceed a number of shares equal to three times the number of shares of common stock issuable under the Warrants as of the Closing Date.

The Note bears interest at the rate of 10% per annum. All interest and principal must be paid twenty-five months after the date of the first borrowing under the Note (the “Maturity Date”). The outstanding balance on the Note is convertible into common stock, at Typenex’s option, at $3.00 per share (the “Optional Conversion”).

Beginning on the date that is six months after the date of the first borrowing and on the same day of each month thereafter until the Maturity Date, we must pay to Typenex the lesser of (i) $82,875, plus the sum of any accrued and unpaid interest, or (ii) the then outstanding balance under the Note. Payments of each installment amount may be made in cash or, as long as we are in compliance with certain terms and conditions set forth in the Note, by converting such installment amount into our common stock. The conversion price for each installment conversion will be the lesser of (i) the $3.00, and (ii) 70% (the “Conversion Factor”) of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion (the “Market Price”), provided that if at any time the average of the three lowest closing bid prices in the 20 trading days immediately preceding any date of measurement is below $1.00, then in such event the then-current Conversion Factor shall be reduced to 65% for all future Conversions, subject to other reductions set forth in the Note. In the event we elect to prepay all or any portion of the Note, we are required to pay to Typenex an amount in cash equal to 125% multiplied by the sum of all principal, interest and any other amounts owing. The Note is secured by all of our assets.

On a date that is 20 trading days from each date that we deliver conversion shares to Typenex, there is a true-up date in which we will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.

13

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

On August 15, 2014, we received net cash proceeds from our initial borrowing under the Note of $225,000 as follows: total initial borrowing of $282,500 less the $32,500 of Fees and OID applicable to the initial borrowing of $25,000. We expensed the Fees immediately as interest expense as the initial borrowing and all subsequent tranches were immediately convertible into our common stock by the lender.

In addition, Typenex has the option to convert all or any part of the outstanding balance of principal, interest, OID and other fees (the “Conversion Feature”) in six tranches; an initial tranche of $282,500 plus interest and other fees owed and five subsequent tranches of $275,000 plus interest and other fees owed for an aggregate total of $1,657,500 plus interest and other fees owed at a conversion price of $3.00 per share. Currently, only the $282,500 initial tranche is conversion eligible. The five subsequent $275,000 tranches become conversion eligible if and when Typenex repays to us the corresponding $250,000 Investor Note(s).

With regards to our $282,500 initial borrowing, on August 15, 2014, we recorded the $25,000 of OID plus the $118,373 fair value of the first Warrant issued, plus $139,127 of the $151,937 fair value of the initial borrowing conversion feature, or, in total, $282,500, as debt discount and recorded the excess, $12,810, as loss on origination of derivative liability in our condensed statements of operations. We are amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.

	Nine Months Ended September 30, 2014
Debt discount - OID	$	25,000
Debt discount – Warrant #1		118,373
Debt discount – conversion feature		151,937
Less: loss on origination of derivative		(12,810	)
Debt discount – beginning balance		282,500
Less: amortization of debt discount		(47,083	)
Unamortized debt discount – end of period	$	235,417

With regards to the remaining $1,375,000 owed under the Note, we recorded the remaining $125,000 of OID plus the $576,151 fair value of the remaining Warrants issued, or, in total, $701,151, as debt discount. We are amortizing the $701,151 debt discount on a straight line basis, which approximates the effective interest method, over the twenty-five month term of the Note.

Our unamortized debt discount applicable to the noncurrent portion of the Note consists of:

	Nine Months Ended September 30, 2014
Debt discount - OID	$	125,000
Debt discount – Warrants #2 - #6		576,151
Debt discount – beginning balance		701,151
Less: amortization of debt discount		(42,069	)
Unamortized debt discount – end of period	$	659,082

14

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

Our convertible note, net consists of:

	Nine Months Ended September 30, 2014
Note	$	1,657,500
Debt discount – OID		(150,000	)
Debt discount – Warrants		(694,524	)
Debt discount – conversion feature		(151,937	)
Debt discount – conversion feature expensed as loss on origination of derivative		12,810
Convertible note, net – beginning of period		673,849
Amortization of debt discount		89,152
Convertible note, net – end of period	$	763,001

During the three and nine months ended September 30, 2014, we recorded debt discount amortization and interest expense of $89,152 and $21,312, respectively, applicable to this Note.

The fair value of the conversion feature applicable to the $21,312 of accrued interest was $11,609 and this amount was recorded as interest expense and an increase to our derivative liability in our condensed financial statements.

NOTE 13 – NOTES PAYABLE, RELATED PARTIES

In December 2011, we entered into a Revolving Promissory Note (the “Revolving Note”) with Ms. Stoppenhagen, our former president and director. Under the terms of the Revolving Note, Ms. Stoppenhagen agreed to advance us, from time to time and at our request, amounts up to an aggregate of $100,000 until December 31, 2013, with all advances be paid on or before December 31, 2013, and interest accruing from the date of any advances on any principal amount withdrawn, and on unpaid interest thereon, at the rate of six percent (6%) per annum, compounded annually. As of September 30, 2014 and December 31, 2013, nothing was owed under the Revolving Note.

On September 30, 2013, we issued a Convertible Note (the "Convertible Note") for $50,000 to NYX Capital Advisors, Inc. (“NYX”), an entity owned by Ms. Stoppenhagen’s husband, in connection with $50,000 cash paid by NYX.  The Convertible Note bears no interest and was convertible at any time, at the option of the holder, into 10,000,000 shares of our common stock at $0.005 per share.  The Convertible Note was converted into our common shares on February 24, 2014.

NOTE 14 – STOCKHOLDERS’ EQUITY

Change of control

On February 27, 2014, NYX and Mr. Paul Enright, our former President, entered into a Stock Purchase Agreement, pursuant to which NYX sold to Mr. Enright an aggregate of 10,000,000 shares of our common stock, representing approximately 87% of our issued and outstanding shares as of that date.

Stock split

On March 21, 2014, we effected a four-for-one stock split of our common stock in the form of a stock dividend of three shares of common stock for each share of common stock outstanding to stockholders of record on March 19, 2014.

15

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

Equity offering

On March 26, 2014, we sold 600,000 units for a total amount of $900,000 to 45 accredited investors. Each Unit consisted of one share of our common stock, two A Warrants and three B Warrants. Each A Warrant entitles the holder to purchase one share of our common stock at a price of $7.50 per share during the two year period commencing April 1, 2014, and the A Warrants are callable once our common stock has traded at a price of at least $15.00 for 20 consecutive trading days.  Each B Warrant entitles the holder to purchase one share of our common stock at a price of $15.00 per share during the three year period commencing April 1, 2014, and the B Warrants are callable once our common stock has traded at a price of at least $22.00 for 20 consecutive trading days.  

Change in Authorized Share Capital

Effective May 2, 2014, we increased the authorized number of our preferred shares from five million to ten million and the authorized number of our common shares from 50 million to 100 million. At the same time we also changed the par value of both our preferred and common stock from $0.001 per share to no par value per share.

Common Stock Issued For Services

On August 14, 2014, we issued 10,000 shares of common stock valued at $9,200, based on the previous trading day’s closing price as consideration for marketing services. The $9,200 is included in included in sales and marketing expense in our condensed statements of operations.

On August 15, 2014, we issued 20,000 shares of common stock valued at $24,800, based on the previous trading day’s closing price as consideration for consulting services. The $24,800 is included in included in general and administrative expense in our condensed statements of operations.

On August 25, 2014, we committed to issued 40,000 shares of common stock valued at $88,000, based on the previous trading day’s closing price as consideration for a 50% ownership interest in CRD. The $88,000 is included in included in equity method investments on our condensed balance sheets. The $88,000 of common stock is included in common stock yet to be issues on our condensed balance sheets.

On September 17, 2014, we issued 150,000 shares of common stock valued at $162,000, based on the previous trading day’s closing price as consideration for prepaid investor relations services. The $162,000 is included in prepaid expenses and other assets on our condensed balance sheets.

Warrants:

The following table summarizes our share warrants outstanding as of September 30, 2014 and December 31, 2013:

	September 30, 2014
	Number of Shares		Weighted Average Remaining Life (years)		Weighted Average Exercise Price
Warrants outstanding, beginning of period		—		—	$	—
Issued		3,997,692		1.8		9.75
Exercised		—		—		—
Expired		—		—		—
Warrants outstanding, end of period		3,997,692		1.8	$	9.75
Warrants exercisable, September 30, 2014		3,170,044		1.6	$	11.52

16

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 15 –COMMITMENTS AND CONTINGENCIES

Contractual Obligations and Commercial Commitments

On May 6, 2014, we entered into a consultancy agreement with two third party doctors that has a nine month term which can be renewed and/or extended by mutual agreement.  The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the three and nine months ended September 30, 2014, we have recognized $100,000 and $150,000 of the $200,000 cash payment obligations as research and development expenses in our condensed statements of operations. At September 30, 2014, $100,000 is included in accrued expenses on our condensed balance sheet. The value of the 100,000 shares will be recognized upon achievement of the goals, currently anticipated to be during the fourth quarter of 2014.

Legal Proceedings

We were not subject to any legal proceedings during the three and nine months ended September 30, 2014, and, to the best of our knowledge, no legal proceedings are pending or threatened.

NOTE 16 –DISCONTINUED OPERATIONS

On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.  See Note 1 for further detail on our change in operations.

The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2014		2013			2014			2013
Revenues	$	—	$	32,278		$	20,684		$	91,144
Operating expenses:
Selling, general and administrative		—		30,870			63,872			56,601
Depreciation		—		6,986			—			20,299
Loss on disposal of assets		—		—			15,704			—
Total operating expenses		—		37,856			79,576			76,900
Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
Provision for income taxes		—		—			—			—
Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244

Our assets held for sale consist of the following and are included in assets of discontinued operations on our condensed balance sheets:

	September 30, 2014		December 31, 2013
Equipment	$	—	$	17,616

17

UNITED CANNABIS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

NOTE 17 – SUBSEQUENT EVENTS

On October 22, 2014, we issued 50,000 shares of common stock valued at $24,000 based on the previous trading day’s closing price as consideration for prepaid investor relations services.

In accordance with ASC 855-10 we have analyzed its operations subsequent to September 30, 2014 to the date these condensed financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements.

18

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion will assist in the understanding of our financial position and results of operations. The information below should be read in conjunction with the condensed financial statements, the related notes to the condensed financial statements and our Annual Report on Form 10-K for the year ended December 31, 2013.

In addition to historical information, this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 regarding our expectations concerning our future operations, earnings and prospects. On the date the forward-looking statements are made, the statements represent our current expectations, but the expectations concerning our future operations, earnings and prospects may change. Our expectations involve risks and uncertainties (both favorable and unfavorable) and are based on many assumptions that we believe to be reasonable, but such assumptions may ultimately prove to be inaccurate or incomplete, in whole or in part. Accordingly, there can be no assurances that our expectations and the forward-looking statements will be correct. Please refer to the our most recent Annual Report on Form 10-K for a description of risk factors that could cause actual results to differ (favorably or unfavorably) from the expectations stated in this discussion. We disclaim any obligation to update any of these forward-looking statements except as required by law.

Corporate Background

United Cannabis Corporation (“we”, “our”, “us” or “UCC”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007.  UCC was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCC, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation’s name to United Cannabis Corporation.  

On March 26, 2014, we entered into a License Agreement with Earnest Blackmon (“Blackmon”), Tony Verzura (“Verzura”) and Chad Ruby (“Ruby”) pursuant to which Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.

In connection with this transaction:

·

Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid (cannabidol or “CBD”) therapy program called “A.C.T. Now”, security, regulatory compliance, and any other methods and processes which relate to the cannabis industry.

·

The territory for this license is the entire world and the license runs in perpetuity.  There are no royalty payments under the License Agreement.

·

Blackmon, Verzura and Ruby were appointed to our board of directors effective April 8, 2014.  

·

Blackmon was elected as our President, Ruby was elected as Chief Operating Officer and Verzura was elected as Vice President. On June 24, 2014, Blackmon was elected as our CEO.

·

A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.

As a result of this transaction our business plan has changed.  We are beginning to create partnerships with businessmen, entrepreneurs, scientists and others, both domestically and internationally, for the purpose of developing cannabis-based products worldwide.

For example, we are starting to enter into licensing and consulting agreements with partners who desire to license our entire turnkey seed-to-sale business model in jurisdictions where it is legal to do so, and we plan to typically receive a percentage of their gross revenues as our fee.  In addition to licensing our intellectual property, we are offering consulting services on the design and buildout of cultivation facilities; we offer training and staffing services; and we will assist our partners in finding the right locations for cultivation facilities.  We provide our partners access to our genetic catalogue which includes over 15 CBD strains, over 150 THC strains and over 30 Cannabis Cup winners.   

19

We also provide our partners access to our full range of extracted/infused medical products. Our plan includes licensing our intellectual property for whole plant activated oils, smokable concentrates, infused products, topical lotions, pills, sublingual transdermal patches and our partners will have access to future technology and products that we develop.

Our goals are to establish strong cultivation positions through our local partners in markets where it is legal and use these revenues to develop new cannabinoid-based drugs for clinical FDA approval patents.

On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.

Results of Operations

Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013

Revenue and Cost of Goods Sold

Revenue and cost of goods sold were $91,113 and $2,136, respectively, during the three months ended September 30, 2014, as compared to $0 during the three months ended September 30, 2013, as we began our new business in 2014. Our revenues were comprised of our recognition of $75,000 of deferred consulting revenue and $16,113 of licensing fees. Our costs of goods sold, $2,136, consisted of materials and supplies related to proprietary processes being licensed by us.

Sales and Marketing Expenses

Sales and marketing expenses were $20,205 and $0 for the three months ended September 30, 2014 and 2013, respectively. The increase in sales and marking expenses was due to the new business we entered into after our change in control. Our sales and marketing expenses were mainly comprised of third party consulting fees during the three months ended September 30, 2014.

Research and Development Expenses

Research and development expenses (“R&D”) were $94,751 and $0 for the three months ended September 30, 2014 and 2013, respectively. The increase in R&D was due to the new business we entered into after our change in control. Our R&D expenses during the three months ended September 30, 2014, were mainly comprised of costs associated with a third party consultancy agreement.

General and Administrative Expenses

General and administrative expenses (“G&A”) were $522,421 and $21,694 for the three months ended September 30, 2014 and 2013, respectively. The increase in general and administrative expenses was due to the new business we entered into after our change in control.

For the three months ended September 30, 2014, our G&A consisted of $172,303 of wages and related, $105,134 of professional fees, $175,000 of business development expense and $69,984 of travel and office related expense.

Other Nonoperating Expense, net

Our other nonoperating expense totaled $158,238, net, during the three months ended September 30, 2014, as compared to $0 during the three months ended September 30, 2013. During this period, interest income of $13,154 was offset by the following: interest expense of $67,488, amortization of debt discount of $89,152, loss on origination of derivative liability of $12,810 and loss on revaluation of derivative liability of $1,942.

Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013

Revenue and Cost of Goods Sold

Revenue and cost of goods sold were $91,113 and $2,136, respectively, during the nine months ended September 30, 2014, as compared to $0 during the nine months ended September 30, 2013, as we began our new business in 2014. Our revenues were comprised of our recognition of $75,000 of deferred consulting revenue and $16,113 of licensing fees. Our costs of goods sold, $2,136, consisted of materials and supplies related to proprietary processes being licensed by us.

20

Sales and Marketing Expenses

Sales and marketing expenses were $94,363 and $0 for the nine months ended September 30, 2014 and 2013, respectively. The increase in sales and marking expenses was due to the new business we entered into after our change in control. Our sales and marketing expenses were mainly comprised of third party consulting fees during the nine months ended September 30, 2014.

Research and Development Expenses

Research and development expenses (“R&D”) were $170,805 and $0 for the nine months ended September 30, 2014 and 2013, respectively. The increase in R&D was due to the new business we entered into after our change in control. Our R&D expenses during the nine months ended September 30, 2014, were mainly comprised of costs associated with a third party consultancy agreement.

General and Administrative Expenses

General and administrative expenses were $946,562 and $32,471 for the nine months ended September 30, 2014 and 2013, respectively. The increase in general and administrative expenses was due to the new business we entered into after our change in control.

For the nine months ended September 30, 2014, our general and administrative expenses consisted of $380,765 of wages and contract labor, $260,682 of professional fees, $175,000 of business development expenses and $130,115 of travel and office related expense.

Other Nonoperating Expense, net

Our other nonoperating expense totaled $158,213, net, during the nine months ended September 30, 2014, as compared to $0 during the nine months ended September 30, 2013. During this period, interest income of $13,179 was offset by the following: interest expense of $67,488, amortization of debt discount of $89,152, loss on origination of derivative liability of $12,810 and loss on revaluation of derivative liability of $1,942.

Discontinued Operations

On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.  

The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2014		2013			2014			2013
Revenues	$	—	$	32,278		$	20,684		$	91,144
Operating expenses:
Selling, general and administrative		—		30,870			63,872			56,601
Depreciation		—		6,986			—			20,299
Loss on disposal of assets		—		—			15,704			—
Total operating expenses		—		37,856			79,576			76,900
Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
Provision for income taxes		—		—			—			—
Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244

21

Liquidity and Capital Resources

Our condensed financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2014, we incurred losses of $1,339,858 and used $1,093,057 of cash in our operating activities. As of September 30, 2014, we had a working capital deficit of $306,674 and an accumulated deficit of $1,496,461.  Our ability to continue as a going concern depends on our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities when they come due. There is no assurance that these events will be satisfactorily completed.

Net cash used in operating activities for the nine months ending September 30, 2014 and 2013 was $1,093,057 and $23,060, respectively. This increase was primarily due to the expenses incurred in connection with our new business as a result of our change in control in March of 2014.

Net cash used in investing activities for the nine months ending September 30, 2014 and 2013 was $50,000 and $18,215, respectively. This increase was due to a $50,000 equity method investment completed during the current period compared to fixed asset purchases totaling $18,215 in the nine months ending September 30, 2013.

Net cash provided by (used in) financing activities for the nine months ending September 30, 2014 and 2013 was $1,300,000 and $0, respectively. The increase was due to $900,000 from the sale of our common stock, $175,000 of borrowings under our note payable and $225,000 of borrowings under our convertible note payable. During the nine months ending September 30, 2013 we both received and repaid $50,000 under our note payable related party.

We believe that we have sufficient capital to fund our current plans, but we plan to raise additional capital through the sale of equity in order to take advantage of some of the opportunities available to grow our business.

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the condensed financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 - "Summary of Significant Accounting Policies" to the condensed financial statements contained in this Quarterly Report certain critical accounting policies that affect the more significant judgments and estimates used in the preparation of our condensed financial statements.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Contractual Obligations

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide this information.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

22

ITEM 4.

CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures: We conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2014, and he has concluded that our financial controls and procedures are adequate.  Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded as of September 30, 2014, that our disclosure controls and procedures are effective to a reasonable assurance level of achieving such objectives.

(b) Changes in Internal Control over Financial Reporting: There were no changes in our internal control over financial reporting during the second quarter ending September 30, 2014, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

We are not a party to any material legal proceedings.

ITEM 1A.

RISK FACTORS.

Not applicable for smaller reporting companies.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three months ended September 30, 2014, we issued a total of 30,000 shares of our common stock to two consultants for marketing and consulting services valued at a total of $34,000 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

During the three months ended September 30, 2014, we issued 150,000 shares of our common stock to an investor relations consultant for prepaid services valued at a total of $162,000 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuance of these shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES AND USE OF PROCEEDS.

None

ITEM 4.

MINES SAFETY DISCLOSURES.

Not applicable to our Company.

ITEM 5.

OTHER INFORMATION.

None

ITEM 6.

EXHIBITS.

Exhibits
31	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Security Exchange Act Rule 13a-14 and 15d-14.
32	Certification of the Company’s Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	XBRL Exhibits

24

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UNITED CANNABIS CORPORATION
Date: November 19, 2014	By:	/s/ Earnest Blackmon
		Earnest Blackmon
		Chief Executive Officer and Principal Financial Officer

25

EX-31

EXHIBIT 31

UNITED CANNABIS CORPORATION

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to

Securities Exchange Act Rules 13a-14 and 15d-14

I, Earnest Blackmon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of United Cannabis Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. As the registrant’s Principal Executive Officer and Principal Financial Officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and I have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	I have disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 19, 2014	/s/ Earnest Blackmon
	Name: Earnest Blackmon Title: CEO and Principal Financial Officer

EX-32

EXHIBIT 32

UNITED CANNABIS CORPORATION

CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,

UNITED STATES CODE)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), the undersigned officer of United Cannabis Corporation (the “Company”), does hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), to the best of the undersigned’s knowledge that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 19, 2014

/s/ Earnest Blackmon

Name: Earnest Blackmon

Title: CEO and Principal Financial Officer

XML

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Narrative) (Details) (WeedMD RX Inc. (''WMD'') [Member])	0 Months Ended	1 Months Ended
	May 30, 2014	May 31, 2014 USD ($)	May 31, 2014 CAD	May 01, 2014 USD ($)	May 01, 2014 CAD
Schedule of Cost-method Investments [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Equity investment		4.29%
Exercise price of warrants received to purchase shares			0.50
Minimum number of Series A Warrants exercised that would require all warrants received to be exercised		800,000
Common shares, price per share				$ 0.50	0.50
Warrants, price per warrant		$ 0.10
Value assigned to the cost of the common shares classified as a long term asset		$ 593,750
Fair value assigned as the cost to the warrants classified as a current asset		$ 300,000

XML

NOTES PAYABLE, RELATED PARTIES (Details) (USD $)			9 Months Ended			1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Convertible Debt [Member]	Sep. 30, 2013 Convertible Debt [Member]	Aug. 13, 2014 Convertible Debt [Member]	Dec. 31, 2011 Former President [Member] Revolving Promissory Note [Member]	Sep. 30, 2014 Former President [Member] Revolving Promissory Note [Member]	Dec. 31, 2013 Former President [Member] Revolving Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount				$ 50,000		$ 100,000
Debt instrument, interest rate						6.00%
Debt instrument, maturity date						Dec. 31, 2013
Convertible note payable, related party		$ 50,000
Number of common stock shares debt instrument can be converted to				10,000,000
Debt conversion, price per share				$ 0.005	$ 3.00
Debt instrument, conversion date			Feb. 24, 2014

XML

FAIR VALUE MEASUREMENTS (Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis) (Details) (Derivative instruments related to embedded conversion features [Member], USD $)			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Debt discount [Member]	Sep. 30, 2014 Interest expense [Member]	Sep. 30, 2014 Loss on derivative liability [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Derivative liability at the beginning of the period	$ 165,488
Additions to derivative liability recorded in statements of operations			151,937	11,609	1,942
Derivative liability at the end of the period	$ 165,488

XML

STOCKHOLDERS' EQUITY (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Feb. 28, 2014	Sep. 30, 2014	May 02, 2014	May 01, 2014	Dec. 31, 2013
STOCKHOLDERS' EQUITY [Abstract]
Common stock sold under stock purchase agreement, representing approximately 87% of the issued and outstanding shares of the Company		10,000,000
Number of units sold through equity offering	600,000
Proceeds from sale of units	$ 900,000
Per share price A Warrant holders can purchase each share of the Company's common stock during the two year period commencing April 1, 2014	$ 7.50
Per share price B Warrant holders can purchase each share of the Company's common stock during the three year period commencing April 1, 2014	$ 15.00
Preferred stock, shares authorized			10,000,000	10,000,000	5,000,000	10,000,000
Preferred stock, par value per share					$ 0.001
Preferred stock, no par value
Common stock, shares authorized			100,000,000	100,000,000	50,000,000	100,000,000
Common stock, par value per share					$ 0.001
Common stock, no par value

XML

FAIR VALUE MEASUREMENTS (Schedule of liabilities carried at fair value measured on a recurring basis) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 165,488
Recurring basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	165,488
Recurring basis [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Recurring basis [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Recurring basis [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 165,488

XML

DISCONTINUED OPERATIONS (Tables)

9 Months Ended

Sep. 30, 2014

DISCONTINUED OPERATIONS [Abstract]

Schedule of Loss from Discontinued Operations

The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:

	Three Months EndedSeptember 30,				Nine Months Ended September 30,
	2014		2013			2014			2013
Revenues	$	—	$	32,278		$	20,684		$	91,144
Operating expenses:
Selling, general and administrative		—		30,870			63,872			56,601
Depreciation		—		6,986			—			20,299
Loss on disposal of assets		—		—			15,704			—
Total operating expenses		—		37,856			79,576			76,900
Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
Provision for income taxes		—		—			—			—
Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244

XML

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Consultancy agreement, term	6 months
Consultancy agreement, initial payment	$ 50,000
Consultancy agreement, additional payments	50,000
Shares issued for consultancy agreement	100,000
Research and development expenses		94,751		170,805
Cash payment obligations		200,000		200,000
Accrued expenses		$ 100,000		$ 100,000

XML

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Tables)

9 Months Ended

Sep. 30, 2014

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]

Schedule of Fair Value Assumptions Used to Value Warrants

The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the nine months ended September 30, 2014:

Risk free interest rate	0.60	%
Expected term (years)	0.5
Expected volatility	70	%
Expected dividends	0	%

XML

FAIR VALUE MEASUREMENTS (Schedule of components of derivative financial instruments on condensed balance sheets) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]
Embedded derivative liability in convertible debt	$ 153,879
Embedded derivative liability in interest payable	11,609
Total derivative liability	$ 165,488

XML

EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
EQUIPMENT [Abstract]
Equipment		$ 131,584
Less accumulated depreciation and amortization		(113,968)
Equipment, net		$ 17,616

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended			12 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014 Revenue [Member] Customer A [Member]	Sep. 30, 2013 Revenue [Member] Customer A [Member]	Sep. 30, 2014 Revenue [Member] Customer A [Member]	Sep. 30, 2013 Revenue [Member] Customer A [Member]	Sep. 30, 2014 Revenue [Member] Customer B [Member]	Sep. 30, 2013 Revenue [Member] Customer B [Member]	Sep. 30, 2014 Revenue [Member] Customer B [Member]	Sep. 30, 2013 Revenue [Member] Customer B [Member]	Sep. 30, 2014 Accounts Receivable [Member] Customer B [Member]	Dec. 31, 2013 Accounts Receivable [Member] Customer B [Member]	Sep. 30, 2014 Accounts Receivable [Member] Customer C [Member]	Dec. 31, 2013 Accounts Receivable [Member] Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	82.00%		82.00%		10.00%		10.00%		43.00%		57.00%

XML

NOTES PAYABLE (Details) (Unsecured, demand promissory note, WeedMD [Member], USD $)	Sep. 30, 2014	Jul. 07, 2014
Unsecured, demand promissory note | WeedMD [Member]
Short-term Debt [Line Items]
Debt instrument, face amount		$ 175,000
Debt instrument, interest rate		5.00%
Accrued interest payable	$ 2,067

XML

FAIR VALUE MEASUREMENTS (Narrative) (Details) (Convertible Note [Member], Typenex Co-Investment, LLC [Member], USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Aug. 15, 2014
Convertible Note [Member] | Typenex Co-Investment, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument initial borrowing			$ 282,500
Accrued interest	$ 21,312	$ 21,312

XML

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES

9 Months Ended

Sep. 30, 2014

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES

NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES

On May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. (“WMD”), a Canadian private company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represent a 4.29% equity investment in WMD and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at the estimated cost, based on our estimate of the fair value of the securities we received on the date of the transaction.

The warrants entitle us to purchase WMD shares for CDN $0.50 each for a period of nine months from the date the warrant was issued. In addition, we are required to exercise all of these warrants if the holders of our Series A Warrants (see Note 14 below) exercise a minimum of 800,000 of our Series A Warrants prior to the expiration of the WMD warrants.

The WMD common shares were recorded at $0.50 per share based on WMD's most recent sale of their common shares prior to the date of the transaction (CDN $0.50).

The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the nine months ended September 30, 2014:

Risk free interest rate	0.60	%
Expected term (years)	0.5
Expected volatility	70	%
Expected dividends	0	%

The $300,000 fair value assigned as the cost to the WMD warrants has been classified as a current asset as the warrants expire after nine months, while the $593,750 assigned to the cost of the WMD common shares has been classified as a long term asset as these shares do not expire.

XML

EQUITY METHOD INVESTMENTS (Schedule of equity method investments) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Lone Mountain [Member]	Aug. 14, 2014 Lone Mountain [Member]	Dec. 31, 2013 Lone Mountain [Member]	Sep. 30, 2014 Om of Medicine, LLC [Member]	Aug. 15, 2014 Om of Medicine, LLC [Member]	Dec. 31, 2013 Om of Medicine, LLC [Member]	Sep. 30, 2014 OM of Illinois, LLC [Member]	Aug. 31, 2014 OM of Illinois, LLC [Member]	Dec. 31, 2013 OM of Illinois, LLC [Member]	Sep. 30, 2014 Cannibinoid Research And Development Company Limited [Member]	Aug. 25, 2014 Cannibinoid Research And Development Company Limited [Member]	Aug. 15, 2014 Cannibinoid Research And Development Company Limited [Member]	Dec. 31, 2013 Cannibinoid Research And Development Company Limited [Member]
Schedule of Equity Method Investments [Line Items]
Interest owned (as a percentage)			25.00%	25.00%		15.00%	15.00%		33.00%	33.00%		50.00%	50.00%	50.00%
Equity method investments	$ 282,000		$ 50,000	$ 50,000		$ 45,000			$ 99,000			$ 88,000	$ 88,000	$ 88,000

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS [Abstract]

Schedule of liabilities carried at fair value measured on a recurring basis

The following table provides our liabilities carried at fair value measured on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Derivative liability	$	—	$	—	$	165,488	$	165,488

Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis

For the nine month period ended September 30, 2014, the following table reconciles the beginning and ending balances for financial instruments that are carried at fair value measured on a recurring basis:

Derivative liability as of December 31, 2013	$	—
Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
Additions to derivative liability for interest payable conversion feature recorded as interest expense		11,609
Loss on revaluation of derivative liability at period end		1,942
Derivative liability as of September 30, 2014	$	165,488

Schedule of key inputs in valuation of embedded conversion features

The key inputs to this valuation model during the nine months ended September 30, 2014, were as follows:

Risk-free interest rate	0.43% – 0.58%
Dividend yield	—
Volatility	146% – 157%
Expected life in years	1.96 – 2.09
Exercise price	$3.00

Schedule of components of derivative financial instruments on condensed balance sheets

The following tabular presentation reflects the components of derivative financial instruments on our condensed balance sheets at September 30, 2014 and December 31, 2013:

	September 30,  2014		December 31,  2013
Derivative Liabilities:
Embedded derivative liability in convertible debt	$	153,879		$	—
Embedded derivative liability in interest payable		11,609			—
Total derivative liability	$	165,488		$	—

XML

EQUITY METHOD INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2014

EQUITY METHOD INVESTMENTS [Abstract]

Schedule of equity method investments

Our equity method investments consist of:

	September 30,2014		December 31, 2013
Lone Mountain Partners, LLC – 25% interest	$	50,000		$	—
Om of Medicine, LLC – 15% interest		45,000			—
OM of Illinois, LLC – 33% interest		99,000			—
Cannibinoid Research & Development Company Limited – 50%		88,000			—
Total equity method investments	$	282,000		$	—

XML

STOCKHOLDERS' EQUITY (Details 2) (USD $)	0 Months Ended				9 Months Ended
	Sep. 17, 2014	Aug. 25, 2014	Aug. 14, 2014	Aug. 15, 2014	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]
Number of shares of common stock issued for services	150,000		10,000	20,000
Value of shares of common stock issued for services	$ 162,000		$ 9,200	$ 24,800
Number of shares of common stock committed to be issued for services		40,000
Value of shares of common stock committed to be issued for services		88,000
Equity method investments					282,000
Number of Shares
Warrants outstanding, beginning of period (in shares)
Issued (in shares)					3,997,692
Exercised (in shares)
Expired (in shares)
Warrants outstanding, end of period (in shares)					3,997,692
Warrants exercisable at the end of the period (in shares)					3,170,044
Weighted Average Remaining Life (years)
Warrants outstanding, beginning of period					1 year 9 months 18 days
Issued					1 year 9 months 18 days
Warrants exercisable at the end of the period					1 year 7 months 6 days
Warrants outstanding, end of period					1 year 9 months 18 days
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)
Issued (in dollars per share)					$ 9.75
Exercised (in dollars per share)
Warrants outstanding, end of period (in dollars per share)					$ 9.75
Warrants exercisable at the end of the period (in dollars per share)					$ 11.52
Cannibinoid Research And Development Company Limited [Member]
Stockholders Equity [Line Items]
Ownership interest (as a percent)		50.00%		50.00%	50.00%
Equity method investments		88,000		88,000	88,000
Prepaid Expenses and Other Current Assets [Member]
Stockholders Equity [Line Items]
Value of shares of common stock issued for services	162,000
Selling and Marketing Expense [Member]
Stockholders Equity [Line Items]
Value of shares of common stock issued for services			9,200
General and Administrative Expense [Member]
Stockholders Equity [Line Items]
Value of shares of common stock issued for services				$ 24,800

XML

EQUITY METHOD INVESTMENTS (Narrative) (Details) (USD $)						0 Months Ended							0 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Lone Mountain [Member]	Aug. 14, 2014 Lone Mountain [Member]	Dec. 31, 2013 Lone Mountain [Member]	Aug. 31, 2014 Oms [Member]	Sep. 30, 2014 Om of Medicine, LLC [Member]	Aug. 15, 2014 Om of Medicine, LLC [Member]	Dec. 31, 2013 Om of Medicine, LLC [Member]	Sep. 30, 2014 OM of Illinois, LLC [Member]	Aug. 31, 2014 OM of Illinois, LLC [Member]	Dec. 31, 2013 OM of Illinois, LLC [Member]	Aug. 15, 2014 Cannibinoid Research And Development Company Limited [Member]	Sep. 30, 2014 Cannibinoid Research And Development Company Limited [Member]	Aug. 25, 2014 Cannibinoid Research And Development Company Limited [Member]	Dec. 31, 2013 Cannibinoid Research And Development Company Limited [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired (as a percentage)			25.00%	25.00%			15.00%	15.00%		33.00%	33.00%		50.00%	50.00%	50.00%
Equity method investments	$ 282,000		$ 50,000	$ 50,000			$ 45,000			$ 99,000			$ 88,000	$ 88,000	$ 88,000
Commitment to provide services accounted as deferred revenue						144,000
Shares of common stock issuable for acquisition of interest													40,000
Common stock not yet issued														$ 88,000

XML

DEFERRED REVENUE (Tables)

9 Months Ended

Sep. 30, 2014

DEFERRED REVENUE.

Schedule of deferred revenue

Our deferred revenue consists of:

	September 30,2014		December 31,2013
Deferred revenue – WeedMD	$	818,750	$	—
Deferred revenue - Om of Medicine, LLC		45,000		—
Deferred revenue - OM of Illinois, LLC		99,000		—
Less – current portion		(444,000)		—
Total equity method investments	$	518,750	$	—

XML

CONVERTIBLE NOTE PAYABLE (Tables)

9 Months Ended

Sep. 30, 2014

CONVERTIBLE NOTE PAYABLE

Schedule of convertible note payable

Our convertible note payable consists of the following:

	September 30, 2014		December 31, 2013
Convertible note payable-Typenex	$	1,657,500		$	—
Less – current portion		(282,500	)		—
Convertible note payable-noncurrent		1,375,000			—
Less – unamortized discount		(659,082	)		—
Convertible note payable-noncurrent, net	$	715,918		$	—
Convertible note payable-current portion	$	282,500		$	—
Less – unamortized discount		(235,417	)		—
Convertible notes payable-current portion, net	$	47,083		$	—

Schedule of unamortized debt discount applicable to the initial borrowing

We are amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.

	Nine Months Ended September 30, 2014
Debt discount - OID	$	25,000
Debt discount – Warrant #1		118,373
Debt discount – conversion feature		151,937
Less: loss on origination of derivative		(12,810	)
Debt discount – beginning balance		282,500
Less: amortization of debt discount		(47,083	)
Unamortized debt discount – end of period	$	235,417

Schedule of unamortized debt discount applicable to the noncurrent portion of the Note

Our unamortized debt discount applicable to the noncurrent portion of the Note consists of:

	Nine Months Ended September 30, 2014
Debt discount - OID	$	125,000
Debt discount – Warrants #2 - #6		576,151
Debt discount – beginning balance		701,151
Less: amortization of debt discount		(42,069	)
Unamortized debt discount – end of period	$	659,082

Schedule of convertible note, net

Our convertible note, net consists of:

	Nine Months Ended September 30, 2014
Note	$	1,657,500
Debt discount – OID		(150,000	)
Debt discount – Warrants		(694,524	)
Debt discount – conversion feature		(151,937	)
Debt discount – conversion feature expensed as loss on origination of derivative		12,810
Convertible note, net – beginning of period		673,849
Amortization of debt discount		89,152
Convertible note, net – end of period	$	763,001

XML

GOING CONCERN

9 Months Ended

Sep. 30, 2014

GOING CONCERN [Abstract]

GOING CONCERN

NOTE 3 – GOING CONCERN

Our condensed financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2014, we incurred losses of $1,339,858 and used cash of $1,093,057 in our operating activities. As at September 30, 2014, we had a working capital deficit of $306,674 and an accumulated deficit of $1,496,461.  Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

XML

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2014

STOCKHOLDERS' EQUITY [Abstract]

Summary of share warrants outstanding

The following table summarizes our share warrants outstanding as of September 30, 2014 and December 31, 2013:

	September 30, 2014
	Number ofShares		Weighted Average Remaining Life (years)		Weighted Average Exercise Price
Warrants outstanding, beginning of period		—		—	$	—
Issued		3,997,692		1.8		9.75
Exercised		—		—		—
Expired		—		—		—
Warrants outstanding, end of period		3,997,692		1.8	$	9.75
Warrants exercisable, September 30, 2014		3,170,044		1.6	$	11.52

XML

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Schedule of Assumptions) (Details) (Cost-method Investments [Member], Warrant [Member], WeedMD RX Inc. (''WMD'') [Member])	9 Months Ended
	Sep. 30, 2014
Cost-method Investments [Member] | Warrant [Member] | WeedMD RX Inc. (''WMD'') [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Pricing model	Black Scholes
Risk free interest rate	0.60%
Expected term	6 months
Expected volatility	70.00%
Expected dividends	0.00%

XML

CONVERTIBLE NOTE PAYABLE (Details) (USD $)	3 Months Ended		9 Months Ended					0 Months Ended		9 Months Ended		9 Months Ended		0 Months Ended		3 Months Ended	9 Months Ended			0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 Typenex Co-Investment, LLC [Member] Investor Notes	Aug. 13, 2014 Typenex Co-Investment, LLC [Member] Investor Notes	Aug. 13, 2014 Typenex Co-Investment, LLC [Member] Warrant [Member] Item	Aug. 13, 2014 Convertible Note [Member]	Sep. 30, 2014 Convertible Note [Member] Item	Sep. 30, 2013 Convertible Note [Member]	Sep. 30, 2014 Convertible Note [Member] Minimum [Member]	Aug. 13, 2014 Convertible Note [Member] Warrant [Member]	Aug. 13, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member]	Aug. 15, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member] Item	Sep. 30, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member]	Sep. 30, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member]	Sep. 30, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member] Initial tranche [Member]	Aug. 15, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member] Initial tranche [Member]	Aug. 15, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member] Five subsequent tranches [Member] Item	Sep. 30, 2014 Convertible Note [Member] Typenex Co-Investment, LLC [Member] Five subsequent tranches [Member]
Debt Instrument [Line Items]
Convertible note payable	$ 1,657,500		$ 1,657,500
Less - current portion	(282,500)		(282,500)
Convertible note payable-noncurrent	1,375,000		1,375,000
Less - unamortized discount	(659,082)		(659,082)
Convertible note payable-noncurrent, net	715,918		715,918
Convertible note payable-current portion	282,500		282,500
Less - unamortized discount	(235,417)		(235,417)
Convertible notes payable-current portion, net	47,083		47,083
Debt instrument, interest rate														10.00%
Debt instrument, face amount											50,000			1,657,500		1,657,500	1,657,500
Original issue discount														150,000	25,000	(150,000)	(150,000)
Legal expenses														7,500	32,500
Payment of brokerage fees														25,000
Number of warrants issued to purchase shares of common stock								997,692
Number of shares for which warrant became exercisable								170,044
Number of tranches in which remaining warrants are exercisable into number of shares								5
Exercise price (in dollars per share)													$ 3.00
Warrant term								3 years
Frequency of number of shares of common stock issuable under the Warrants								3
Debt instrument, term									25 months
Debt conversion, price per share									$ 3.00		$ 0.005	$ 3.00			$ 3.00
Minimum amount payable plus the sum of any accrued and unpaid interest																	82,875
Conversion Factor (as a percent)												70.00%
Number of lowest closing bid prices in specified trading days immediately preceding the applicable conversion										3
Number of trading days immediately preceding the applicable conversion										20 days
Measurement price (in dollars per share)										$ 1.00
Reduction in conversion factor (as a percent)										65.00%
Percentage of amount required to be payable in cash																12500.00%	12500.00%
Net cash proceeds received from initial borrowing				50,000											225,000
Debt instrument initial borrowing															282,500
Number of tranches in which debt instruments can be converted															6					5
Tranche amount of debt instrument to be converted																			282,500	275,000
Amount of conversion eligible initial tranche																		282,500
Tranche amount of debt instrument to be converted if and when corresponding Investor Notes will be repaid to the entity																					275,000
Notes receivable, face amount						250,000	250,000
Fair value of the first Warrant issued recorded as debt discount under initial borrowing																118,373	118,373
Loss on origination of derivative liability	(1,942)		(1,942)												12,810
Portion of fair value of initial borrowing conversion feature recorded as debt discount under initial borrowing															139,127
Unamortized debt discount applicable to initial borrowing [Abstract]
Debt discount - OID																25,000	25,000
Debt discount - Warrant #1																118,373	118,373
Debt discount - conversion feature															151,937		151,937
Less: loss on origination of derivative	(12,810)		(12,810)														(12,810)
Debt discount - beginning balance																	282,500
Less: amortization of debt discount																	(47,083)
Unamortized debt discount - end of period															282,500	235,417	235,417
Debt instrument remaining borrowing															1,375,000
Original issue discount under remaining borrowing															125,000
Fair value of the Warrant issued recorded as debt discount under remaining borrowing															576,151
Total debt discount under remaining borrowing															701,151
Unamortized debt discount applicable to the noncurrent portion of the Note
Debt discount - OID																125,000	125,000
Debt discount - Warrants #2 - #6																576,151	576,151
Debt discount - beginning balance																	701,151
Less: amortization of debt discount																	42,069
Unamortized debt discount - end of period																659,082	659,082
Components of convertible debt, net
Note											50,000			1,657,500		1,657,500	1,657,500
Debt discount - OID														150,000	25,000	(150,000)	(150,000)
Debt discount - Warrants																(694,524)	(694,524)
Debt discount - conversion feature															151,937		151,937
Debt discount - conversion feature expensed as loss on origination of derivative	(12,810)		(12,810)														(12,810)
Convertible note, net - beginning of period																	673,849
Amortization of debt discount	89,152		89,152													89,152	89,152
Convertible note, net - end of period																763,001	763,001
Debt discount amortization and interest expense	89,152		89,152													89,152	89,152
Accrued interest																21,312	21,312
Fair value of the conversion feature applicable to accrued interest																$ 11,609	$ 11,609

XML

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 189,357	$ 32,414
Accounts receivable	16,113
Investments in non-marketable equity securities	300,000
Due from related party		8,862
Prepaid expenses and other assets	188,450
Assets of discontinued operations		17,616
Total current assets	693,920	58,892
Investments in non-marketable equity securities	593,750
Equity method investments	282,000
Notes and interest receivable	1,263,150
Total assets	2,832,820	58,892
Current liabilities:
Accounts payable	38,571
Accrued expenses	130,452
Derivative liability	165,488
Current portion of deferred revenue	444,000
Note payable	175,000
Current portion of convertible note payable, net	47,083
Convertible note payable, related party		50,000
Total current liabilities	1,000,594	50,000
Long term liabilities:
Deferred revenue, net of current portion	518,750
Convertible note payable, net and net of current portion	715,918
Total liabilities	2,235,262	50,000
Stockholders' equity:
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, no par value; 100,000,000 shares authorized; 43,800,000 (unaudited) and 6,020,000* issued and outstanding, respectively	2,006,019	165,495
Common stock not yet issued, 40,000 shares	88,000
Accumulated deficit	(1,496,461)	(156,603)
Total stockholders' equity	597,558	8,892
Total liabilities and stockholders' equity	$ 2,832,820	$ 58,892

XML

NOTES AND INTEREST RECEIVABLE (Details) (Typenex Co-Investment, LLC [Member], USD $)	0 Months Ended	3 Months Ended	9 Months Ended
	Aug. 13, 2014	Sep. 30, 2014	Sep. 30, 2014
Five unsecured Investor Notes
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, face amount	$ 1,250,000
Notes receivable, interest rate (as a percent)	8.00%
Minimum share price for 20 consecutive days used for exercise of right to call notes receivables	$ 6.00
Period of share price used for exercise of right to call notes receivables	20 days
Interest income		13,150	13,150
Investor Notes
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, face amount	$ 250,000	$ 250,000	$ 250,000

XML

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS

9 Months Ended

Sep. 30, 2014

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS

NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS

Current Operations and Background – United Cannabis Corporation ("we", "our", "us" or "UCC") a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. UCC was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCC, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.

On March 26, 2014, we entered into a License Agreement with Earnest Blackmon ("Blackmon"), Tony Verzura ("Verzura") and Chad Ruby ("Ruby") pursuant to which Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.

In connection with this transaction:

• Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid (cannabidol or "CBD") therapy program called "A.C.T. Now", security, regulatory compliance, and any other methods and processes which relate to the cannabis industry.

• The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.

• Blackmon, Verzura and Ruby were appointed to our board of directors effective April 8, 2014.

• Blackmon was elected as our President, Ruby was elected as Chief Operating Officer and Verzura was elected as Vice President. On June 24, 2014, Blackmon was elected as our CEO and CFO.

• A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.

As a result of this transaction our business plan has changed. We are beginning to create partnerships with businessmen, entrepreneurs, scientists and others, both domestically and internationally, for the purpose of developing cannabis-based products worldwide.

For example, we are starting to enter into licensing and consulting agreements with partners who desire to license our entire turnkey seed-to-sale business model in jurisdictions where it is legal to do so, and we plan to typically receive a percentage of their gross revenues as our fee. In addition to licensing our intellectual property, we are offering consulting services on the design and buildout of cultivation facilities; we offer training and staffing services; and we will assist our partners in finding the right locations for cultivation facilities. We provide our partners access to our genetic catalogue which includes over 15 CBD strains, over 150 THC strains and over 30 Cannabis Cup winners.

We also provide our partners access to our full range of extracted/infused medical products. Our plan includes licensing our intellectual property for whole plant activated oils, smokable concentrates, infused products, topical lotions, pills, sublingual transdermal patches and our partners will have access to future technology and products that we develop.

Our goals are to establish strong cultivation positions through our local partners in markets where it is legal and use these revenues to develop new cannabinoid based drugs for clinical FDA approval patents.

On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.

Government Regulation -Marijuana is a Schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.

As of November 19, 2014, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado, Washington, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana.   However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously.  Any such change in the federal government's enforcement of current federal laws could cause significant financial damage to us.  

XML

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], USD $)	1 Months Ended
	Oct. 22, 2014
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued	50,000
Value of shares of common stock issued	$ 24,000

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Minimum [Member]	Sep. 30, 2014 Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Cash equivalents
Allowance for doubtful accounts
Property, Plant and Equipment [Line Items]
Estimated useful lives of equipment			3 years	5 years

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2014

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

On October 22, 2014, we issued 50,000 shares of common stock valued at $24,000 based on the previous trading day's closing price as consideration for prepaid investor relations services.

In accordance with ASC 855-10 we have analyzed its operations subsequent to September 30, 2014 to the date these condensed financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Convertible notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	337,569		337,569
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	997,692		3,997,692

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2014

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.

	Three Months EndedSeptember 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible notes		337,569		—		337,569		—
Warrants to purchase common stock		997,692		—		3,997,692		—

Schedule of significant concentrations in revenues and accounts receivable

The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.

Percentage of Revenue during the Period Ended

	Three Months Ended					Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
Customer A		82	%		—			82	%		—
Customer B		10	%		—			10	%		—

Percentage of Accounts Receivable during the Period Ended

	September 30,2014			December 31, 2013
Customer B		43	%		—
Customer C		57	%		—

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2014

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2014 and 2013, are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.

Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of the notes payable and notes receivable at September 30, 2014, approximate their respective fair values based on our incremental borrowing rates.

Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2014 and December 31, 2013.

Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.

We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of September 30, 2014 and December 31, 2013.

Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other assets.

Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.

Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.

Equity Method Investments – Our investments in entities representing ownership of at least 15% but less than 50%, where we exercise significant influence, are accounted for under the equity method.

Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.

Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Advertising Costs - All advertising costs are expensed as incurred.

Research and Development Expense - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.

Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.

Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.

	Three Months EndedSeptember 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible notes		337,569		—		337,569		—
Warrants to purchase common stock		997,692		—		3,997,692		—

Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.

The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.

Percentage of Revenue during the Period Ended

	Three Months Ended					Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
Customer A		82	%		—			82	%		—
Customer B		10	%		—			10	%		—

Percentage of Accounts Receivable during the Period Ended

	September 30,2014			December 31, 2013
Customer B		43	%		—
Customer C		57	%		—

Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

XML

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONDENSED BALANCE SHEETS [Abstract]
Preferred stock, no par value
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, no par value
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,800,000	6,020,000	[1]
Common stock, shares outstanding	43,800,000	6,020,000	[1]
Common stock, not yet issued shares	40,000	40,000

[1] The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

XML

CONVERTIBLE NOTE PAYABLE

9 Months Ended

Sep. 30, 2014

CONVERTIBLE NOTE PAYABLE

CONVERTIBLE NOTE PAYABLE

NOTE 12 – CONVERTIBLE NOTE PAYABLE

Our convertible note payable consists of the following:

	September 30, 2014		December 31, 2013
Convertible note payable-Typenex	$	1,657,500		$	—
Less – current portion		(282,500	)		—
Convertible note payable-noncurrent		1,375,000			—
Less – unamortized discount		(659,082	)		—
Convertible note payable-noncurrent, net	$	715,918		$	—
Convertible note payable-current portion	$	282,500		$	—
Less – unamortized discount		(235,417	)		—
Convertible notes payable-current portion, net	$	47,083		$	—

On August 13, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of a 10% convertible promissory note (the “Note”) in the principal amount of $1,657,500 (the “Closing Amount”) convertible into shares of our common stock. The Note has an original issue discount (“OID”) of $150,000. Typenex retained $7,500 of the Closing Amount for due diligence and legal bills related to the transaction and paid $25,000 on our behalf to a third party for brokerage fees (together, the “Fees”). The financing closed on August 13, 2014 (the “Closing Date”). 

In addition, we issued to Typenex warrants (the “Warrants”) to purchase 997,692 shares of our common stock, subject to adjustment in the event of a cashless exercise, as defined in the Warrant. Warrants for 170,044 shares were immediately exercisable with the remainder only becoming exercisable, in five tranches, if and when the Investor Notes (see Note 8 above) are paid. The Warrants are exercisable at $3.00 per share (the “Exercise Price”) for a period of three years on a cash or cashless basis. If we, at any time while the Warrants are outstanding, sell or issue our common stock or securities convertible into or exercisable for shares of our common stock, including common stock issued under the Note, at an effective price per share less than the Exercise Price, then, subject to a few exceptions set forth in the Warrant, the Exercise Price will be reduced to such lower price provided that the number of shares of common stock issuable under the Warrant may not exceed a number of shares equal to three times the number of shares of common stock issuable under the Warrants as of the Closing Date.

The Note bears interest at the rate of 10% per annum. All interest and principal must be paid twenty-five months after the date of the first borrowing under the Note (the “Maturity Date”). The outstanding balance on the Note is convertible into common stock, at Typenex's option, at $3.00 per share (the “Optional Conversion”).

Beginning on the date that is six months after the date of the first borrowing and on the same day of each month thereafter until the Maturity Date, we must pay to Typenex the lesser of (i) $82,875, plus the sum of any accrued and unpaid interest, or (ii) the then outstanding balance under the Note. Payments of each installment amount may be made in cash or, as long as we are in compliance with certain terms and conditions set forth in the Note, by converting such installment amount into our common stock. The conversion price for each installment conversion will be the lesser of (i) the $3.00, and (ii) 70% (the “Conversion Factor”) of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion (the “Market Price”), provided that if at any time the average of the three lowest closing bid prices in the 20 trading days immediately preceding any date of measurement is below $1.00, then in such event the then-current Conversion Factor shall be reduced to 65% for all future Conversions, subject to other reductions set forth in the Note. In the event we elect to prepay all or any portion of the Note, we are required to pay to Typenex an amount in cash equal to 125% multiplied by the sum of all principal, interest and any other amounts owing. The Note is secured by all of our assets.

On a date that is 20 trading days from each date that we deliver conversion shares to Typenex, there is a true-up date in which we will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.

On August 15, 2014, we received net cash proceeds from our initial borrowing under the Note of $225,000 as follows: total initial borrowing of $282,500 less the $32,500 of Fees and OID applicable to the initial borrowing of $25,000. We expensed the Fees immediately as interest expense as the initial borrowing and all subsequent tranches were immediately convertible into our common stock by the lender.

In addition, Typenex has the option to convert all or any part of the outstanding balance of principal, interest, OID and other fees (the “Conversion Feature”) in six tranches; an initial tranche of $282,500 plus interest and other fees owed and five subsequent tranches of $275,000 plus interest and other fees owed for an aggregate total of $1,657,500 plus interest and other fees owed at a conversion price of $3.00 per share. Currently, only the $282,500 initial tranche is conversion eligible. The five subsequent $275,000 tranches become conversion eligible if and when Typenex repays to us the corresponding $250,000 Investor Note(s).

With regards to our $282,500 initial borrowing, on August 15, 2014, we recorded the $25,000 of OID plus the $118,373 fair value of the first Warrant issued, plus $139,127 of the $151,937 fair value of the initial borrowing conversion feature, or, in total, $282,500, as debt discount and recorded the excess, $12,810, as loss on origination of derivative liability in our condensed statements of operations. We are amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.

	Nine Months Ended September 30, 2014
Debt discount - OID	$	25,000
Debt discount – Warrant #1		118,373
Debt discount – conversion feature		151,937
Less: loss on origination of derivative		(12,810	)
Debt discount – beginning balance		282,500
Less: amortization of debt discount		(47,083	)
Unamortized debt discount – end of period	$	235,417

With regards to the remaining $1,375,000 owed under the Note, we recorded the remaining $125,000 of OID plus the $576,151 fair value of the remaining Warrants issued, or, in total, $701,151, as debt discount. We are amortizing the $701,151 debt discount on a straight line basis, which approximates the effective interest method, over the twenty-five month term of the Note.

Our unamortized debt discount applicable to the noncurrent portion of the Note consists of:

	Nine Months Ended September 30, 2014
Debt discount - OID	$	125,000
Debt discount – Warrants #2 - #6		576,151
Debt discount – beginning balance		701,151
Less: amortization of debt discount		(42,069	)
Unamortized debt discount – end of period	$	659,082

Our convertible note, net consists of:

	Nine Months Ended September 30, 2014
Note	$	1,657,500
Debt discount – OID		(150,000	)
Debt discount – Warrants		(694,524	)
Debt discount – conversion feature		(151,937	)
Debt discount – conversion feature expensed as loss on origination of derivative		12,810
Convertible note, net – beginning of period		673,849
Amortization of debt discount		89,152
Convertible note, net – end of period	$	763,001

During the three and nine months ended September 30, 2014, we recorded debt discount amortization and interest expense of $89,152 and $21,312, respectively, applicable to this Note.

The fair value of the conversion feature applicable to the $21,312 of accrued interest was $11,609 and this amount was recorded as interest expense and an increase to our derivative liability in our condensed financial statements.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 19, 2014
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	0001436161
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		43,850,000

XML

NOTES PAYABLE, RELATED PARTIES

9 Months Ended

Sep. 30, 2014

NOTES PAYABLE, RELATED PARTIES [Abstract]

NOTES PAYABLE, RELATED PARTIES

NOTE 13 – NOTES PAYABLE, RELATED PARTIES

In December 2011, we entered into a Revolving Promissory Note (the “Revolving Note”) with Ms. Stoppenhagen, our former president and director. Under the terms of the Revolving Note, Ms. Stoppenhagen agreed to advance us, from time to time and at our request, amounts up to an aggregate of $100,000 until December 31, 2013, with all advances be paid on or before December 31, 2013, and interest accruing from the date of any advances on any principal amount withdrawn, and on unpaid interest thereon, at the rate of six percent (6%) per annum, compounded annually. As of September 30, 2014 and December 31, 2013, nothing was owed under the Revolving Note.

On September 30, 2013, we issued a Convertible Note (the "Convertible Note") for $50,000 to NYX Capital Advisors, Inc. (“NYX”), an entity owned by Ms. Stoppenhagen's husband, in connection with $50,000 cash paid by NYX.  The Convertible Note bears no interest and was convertible at any time, at the option of the holder, into 10,000,000 shares of our common stock at $0.005 per share.  The Convertible Note was converted into our common shares on February 24, 2014.

XML

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
CONDENSED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 91,113			$ 91,113
Cost of goods sold	2,136			2,136
Gross profit	88,977			88,977
Operating expenses:
Sales and marketing	20,205			94,363
Research and development	94,751			170,805
General and administrative	522,421	21,694		946,562		32,471
Total operating expenses	637,377	21,694		1,211,730		32,471
Loss from operations	(548,400)	(21,694)		(1,122,753)		(32,471)
Other income (expense):
Interest income	13,154			13,179
Loss on derivative liability	(1,942)			(1,942)
Interest expense	(67,488)			(67,488)
Loss on origination of derivative liability	(12,810)			(12,810)
Amortization of debt discount	(89,152)			(89,152)
Total other income (expense)	(158,238)			(158,213)
Loss from continuing operations	(706,638)	(21,694)		(1,280,966)		(32,471)
Net income (loss) from discontinued operations		(5,578)		(58,892)		14,244
Net loss	$ (706,638)	$ (27,272)		$ (1,339,858)		$ (18,227)
Net loss per share from continuing operations:
Basic and diluted	$ (0.02)	$ 0.00	[1]	$ (0.03)		$ 0.00	[1]
Net income (loss) per share from discontinued operations:
Basic and diluted		$ 0.00	[1]	$ 0.00	[1]	$ 0.00	[1]
Net income (loss) per common share:
Basic and diluted	$ (0.02)	$ 0.00	[1]	$ (0.03)		$ 0.00	[1]
Basic and diluted weighted-average common shares outstanding:	43,656,304	6,020,000	[2]	43,389,744		6,020,000	[2]

[1] Denotes income or loss of less than $0.01 per share.

[2] The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

XML

EQUITY METHOD INVESTMENTS

9 Months Ended

Sep. 30, 2014

EQUITY METHOD INVESTMENTS [Abstract]

EQUITY METHOD INVESTMENTS

NOTE 7 – EQUITY METHOD INVESTMENTS

Our equity method investments consist of:

	September 30,2014		December 31, 2013
Lone Mountain Partners, LLC – 25% interest	$	50,000		$	—
Om of Medicine, LLC – 15% interest		45,000			—
OM of Illinois, LLC – 33% interest		99,000			—
Cannibinoid Research & Development Company Limited – 50%		88,000			—
Total equity method investments	$	282,000		$	—

On August 14, 2014, we acquired a 25% membership interest in Lone Mountain Partners, LLC, (“Lone Mountain”) for $50,000 and a commitment to provide future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Nevada and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of Lone Mountain. As of September 30, 2014, Lone Mountain did not have any operations or operating activities. We accounted for the $50,000 cash contribution as an equity method investment on our condensed balance sheet.

On August 15, 2014, and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC (together the “Oms”), respectively, in return for a commitment to provide $144,000 of future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Illinois and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of the Oms. As of September 30, 2014, the Oms did not have any operations or operating activities. We accounted for this $144,000 commitment to provide services as deferred revenue in our condensed statements of operations and included this amount in equity method investments on our condensed balance sheets.

On August 15, 2014, we acquired a 50% interest in Cannibinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day's closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as our intellectual property in the operations of CRD. As of September 30, 2014, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our condensed balance sheet. As we have not yet issued the 40,000 shares, the $88,000 is classified as common stock not yet issued on our condensed balance sheets.

XML

EQUIPMENT

9 Months Ended

Sep. 30, 2014

EQUIPMENT [Abstract]

EQUIPMENT

NOTE 6 – EQUIPMENT

Our equipment consists of the following at:

	September 30,2014		December 31, 2013
Equipment	$	—		$	131,584
Less accumulated depreciation		—			(113,968	)
	$	—		$	17,616

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)

9 Months Ended

Sep. 30, 2014

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of Presentation

Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2014 and 2013, are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates

Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.

Financial Instruments

Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of the notes payable and notes receivable at September 30, 2014, approximate their respective fair values based on our incremental borrowing rates.

Cash and Cash Equivalents

Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2014 and December 31, 2013.

Accounts Receivable

Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.

We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of September 30, 2014 and December 31, 2013.

Investments in Non-Marketable Equity Securities

Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other assets.

Inventory

Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.

Equipment

Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.

Equity Method Investments

Equity Method Investments – Our investments in entities representing ownership of at least 15% but less than 50%, where we exercise significant influence, are accounted for under the equity method.

Deferred Revenue

Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.

Revenue Recognition

Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Advertising Costs

Advertising Costs - All advertising costs are expensed as incurred.

Research and Development Expense

Research and Development Expense - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.

Income Taxes

Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.

Net Income (Loss) Per Share

Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.

	Three Months EndedSeptember 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible notes		337,569		—		337,569		—
Warrants to purchase common stock		997,692		—		3,997,692		—

Concentration of Credit Risk

Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.

The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.

Percentage of Revenue during the Period Ended

	Three Months Ended					Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
Customer A		82	%		—			82	%		—
Customer B		10	%		—			10	%		—

Percentage of Accounts Receivable during the Period Ended

	September 30,2014			December 31, 2013
Customer B		43	%		—
Customer C		57	%		—

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

XML

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2014

STOCKHOLDERS' EQUITY [Abstract]

STOCKHOLDERS' EQUITY

NOTE 14 – STOCKHOLDERS' EQUITY

Change of control

On February 27, 2014, NYX and Mr. Paul Enright, our former President, entered into a Stock Purchase Agreement, pursuant to which NYX sold to Mr. Enright an aggregate of 10,000,000 shares of our common stock, representing approximately 87% of our issued and outstanding shares as of that date.

Stock split

On March 21, 2014, we effected a four-for-one stock split of our common stock in the form of a stock dividend of three shares of common stock for each share of common stock outstanding to stockholders of record on March 19, 2014.

Equity offering

On March 26, 2014, we sold 600,000 units for a total amount of $900,000 to 45 accredited investors. Each Unit consisted of one share of our common stock, two A Warrants and three B Warrants. Each A Warrant entitles the holder to purchase one share of our common stock at a price of $7.50 per share during the two year period commencing April 1, 2014, and the A Warrants are callable once our common stock has traded at a price of at least $15.00 for 20 consecutive trading days.  Each B Warrant entitles the holder to purchase one share of our common stock at a price of $15.00 per share during the three year period commencing April 1, 2014, and the B Warrants are callable once our common stock has traded at a price of at least $22.00 for 20 consecutive trading days.  

Change in Authorized Share Capital

Effective May 2, 2014, we increased the authorized number of our preferred shares from five million to ten million and the authorized number of our common shares from 50 million to 100 million. At the same time we also changed the par value of both our preferred and common stock from $0.001 per share to no par value per share.

Common Stock Issued For Services

On August 14, 2014, we issued 10,000 shares of common stock valued at $9,200, based on the previous trading day's closing price as consideration for marketing services. The $9,200 is included in included in sales and marketing expense in our condensed statements of operations.

On August 15, 2014, we issued 20,000 shares of common stock valued at $24,800, based on the previous trading day's closing price as consideration for consulting services. The $24,800 is included in included in general and administrative expense in our condensed statements of operations.

On August 25, 2014, we committed to issued 40,000 shares of common stock valued at $88,000, based on the previous trading day's closing price as consideration for a 50% ownership interest in CRD. The $88,000 is included in included in equity method investments on our condensed balance sheets. The $88,000 of common stock is included in common stock yet to be issues on our condensed balance sheets.

On September 17, 2014, we issued 150,000 shares of common stock valued at $162,000, based on the previous trading day's closing price as consideration for prepaid investor relations services. The $162,000 is included in prepaid expenses and other assets on our condensed balance sheets.

Warrants:

The following table summarizes our share warrants outstanding as of September 30, 2014 and December 31, 2013:

	September 30, 2014
	Number ofShares		Weighted Average Remaining Life (years)		Weighted Average Exercise Price
Warrants outstanding, beginning of period		—		—	$	—
Issued		3,997,692		1.8		9.75
Exercised		—		—		—
Expired		—		—		—
Warrants outstanding, end of period		3,997,692		1.8	$	9.75
Warrants exercisable, September 30, 2014		3,170,044		1.6	$	11.52

XML

DEFERRED REVENUE

9 Months Ended

Sep. 30, 2014

DEFERRED REVENUE.

DEFERRED REVENUE.

NOTE 10 – DEFERRED REVENUE

Our deferred revenue consists of:

	September 30,2014		December 31,2013
Deferred revenue – WeedMD	$	818,750	$	—
Deferred revenue - Om of Medicine, LLC		45,000		—
Deferred revenue - OM of Illinois, LLC		99,000		—
Less – current portion		(444,000)		—
Total equity method investments	$	518,750	$	—

As described in Note 4 above, on May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and, based on discussions with WMD, we expect to deliver consulting services and use of our intellectual property to WMD on a consistent monthly basis during a three year period beginning June 1, 2014. Accordingly, we began recognizing $25,000 of deferred revenue per month totaling $75,000 during the three and nine months ending September 30, 2014. At September 30, 2014, we expect to recognize $300,000 of the $818,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $300,000 as a current liability on our condensed balance sheets.

As described in Note 7 above, on August 15, 2014 and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC, respectively, in return for a commitment to provide $144,000 of future services to these entities. As of September 30, 2014, the Oms did not have any operations or operating activities; however, we expect to satisfy our future service obligations during the next twelve months and accordingly, we have classified the $144,000 as a current liability in our condensed balance sheets.

XML

NOTES AND INTEREST RECEIVABLE

9 Months Ended

Sep. 30, 2014

NOTES AND INTEREST RECEIVABLE [Abstract]

NOTES AND INTEREST RECEIVABLE

NOTE 8 – NOTES AND INTEREST RECEIVABLE

Notes Receivable

On August 13, 2014, in conjunction with the $1,657,500 Typenex Co-Investment, LLC (“Typenex”) convertible promissory note more fully described in Note 12 below, we received five, unsecured, $250,000 Investor Notes bearing interest at 8% per annum, totaling $1,250,000 that mature with respect to principal and interest on September 13, 2016. The Investor Notes can be prepaid at any time, without penalty, by Typenex and Typenex has certain rights to offset the amounts owed to us by amounts we owe to them in accordance with the terms of the Investor Notes. We have the right to call the Investor Notes if the share price of our common stock (as further defined in the Investor Notes terms and conditions) exceeds $6.00 per share for 20 consecutive trading days.

Our intention in entering into this arrangement with Typenex is that the Investor Notes will provide us with a mechanism to obtain additional cash funding. Upon our request and with Typenex's consent, we can redeem individual Investor Notes for cash before meeting the price threshold of $6.00 per share for 20 consecutive days at which point we have the right to demand repayment of these Investor Notes from Typenex without requiring their consent.

During the three and nine months ended September 30, 2014, we recognized $13,150 of interest income applicable to these Investor Notes and this amount is included in notes and interest receivable on our condensed balance sheets.

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 9 – FAIR VALUE MEASUREMENTS

We have adopted the guidance of ASC 820, Fair Value Measurement, which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The following table provides our liabilities carried at fair value measured on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Derivative liability	$	—	$	—	$	165,488	$	165,488

We did not have any liabilities carried at fair value measured on a recurring basis as of December 31, 2013.

We value our derivative instruments related to embedded conversion features from the initial borrowing of $282,500 under the Typenex convertible note payable (see Note 12 below) and accrued interest of $21,312 thereon in accordance with the Level 3 guidelines. For the nine month period ended September 30, 2014, the following table reconciles the beginning and ending balances for financial instruments that are carried at fair value measured on a recurring basis:

Derivative liability as of December 31, 2013	$	—
Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
Additions to derivative liability for interest payable conversion feature recorded as interest expense		11,609
Loss on revaluation of derivative liability at period end		1,942
Derivative liability as of September 30, 2014	$	165,488

The fair values of embedded conversion features issued with our convertible debt and accrued interest payable were estimated using the Black-Scholes option pricing model. The key inputs to this valuation model during the nine months ended September 30, 2014, were as follows:

Risk-free interest rate	0.43% – 0.58%
Dividend yield	—
Volatility	146% – 157%
Expected life in years	1.96 – 2.09
Exercise price	$3.00

The following tabular presentation reflects the components of derivative financial instruments on our condensed balance sheets at September 30, 2014 and December 31, 2013:

	September 30,  2014		December 31,  2013
Derivative Liabilities:
Embedded derivative liability in convertible debt	$	153,879		$	—
Embedded derivative liability in interest payable		11,609			—
Total derivative liability	$	165,488		$	—

XML

NOTES PAYABLE

9 Months Ended

Sep. 30, 2014

NOTES PAYABLE [Abstract]

NOTES PAYABLE

NOTE 11 – NOTES PAYABLE

On July 7, 2014, we issued a $175,000, unsecured, demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. Interest expense during the three and nine months ending September 30, 2014, was $2,067 and accrued interest payable in that amount is included in accrued expenses on our condensed balance sheets.

XML

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Sep. 30, 2014	Mar. 26, 2014	Dec. 31, 2013
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]
Amount of payable owed to former officer and director, exchanged for assets sold	$ 15,000
Number of common shares issued in exchange for certain intellectual property	38,690,000
Total number of common shares previously outstanding, cancelled during period			41,690,000
Common stock, shares outstanding		43,800,000	43,620,000	6,020,000	[1]

[1] The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

XML

DEFERRED REVENUE (Details) (USD $)			0 Months Ended	3 Months Ended	9 Months Ended			0 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	May 30, 2014 WeedMD [Member]	Sep. 30, 2014 WeedMD [Member]	Sep. 30, 2014 WeedMD [Member]	May 31, 2014 WeedMD [Member]	Dec. 31, 2013 WeedMD [Member]	Aug. 31, 2014 Oms [Member]	Sep. 30, 2014 Om of Medicine, LLC [Member]	Aug. 15, 2014 Om of Medicine, LLC [Member]	Dec. 31, 2013 Om of Medicine, LLC [Member]	Sep. 30, 2014 OM of Illinois, LLC [Member]	Aug. 31, 2014 OM of Illinois, LLC [Member]	Dec. 31, 2013 OM of Illinois, LLC [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue current and noncurrent				$ 818,750	$ 818,750				$ 45,000			$ 99,000
Less - current portion	(444,000)			300,000	300,000
Total equity method investments	518,750
Common shares received in exchange for future consulting services and use of our intellectual property			1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property			3,000,000
Fair value of securities recorded as deferred revenue			893,750
Deferred revenue recognized per month				25,000	25,000
Total deferred revenue recognized				$ 75,000	$ 75,000			$ 144,000
Interest acquired (as a percentage)						4.29%			15.00%	15.00%		33.00%	33.00%

XML

DISCONTINUED OPERATIONS

9 Months Ended

Sep. 30, 2014

DISCONTINUED OPERATIONS [Abstract]

DISCONTINUED OPERATIONS

NOTE 16 –DISCONTINUED OPERATIONS

On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.  See Note 1 for further detail on our change in operations.

The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:

	Three Months EndedSeptember 30,				Nine Months Ended September 30,
	2014		2013			2014			2013
Revenues	$	—	$	32,278		$	20,684		$	91,144
Operating expenses:
Selling, general and administrative		—		30,870			63,872			56,601
Depreciation		—		6,986			—			20,299
Loss on disposal of assets		—		—			15,704			—
Total operating expenses		—		37,856			79,576			76,900
Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
Provision for income taxes		—		—			—			—
Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244

Our assets held for sale consist of the following and are included in assets of discontinued operations on our condensed balance sheets:

	September 30,2014		December 31, 2013
Equipment	$	—		$	17,616

XML

PREPAID EXPENSES AND OTHER ASSETS (Tables)

9 Months Ended

Sep. 30, 2014

PREPAID EXPENSES AND OTHER ASSETS [Abstract]

Schedule of prepaid expenses and other assets

 Prepaid expenses and other assets consist of:

	September 30,2014		December 31, 2013
Prepaid investor relations services	$	162,000		$	—
Prepaid accounting fees		550			—
Interest receivable		25,900			—
	$	188,450		$	—

XML

FAIR VALUE MEASUREMENTS (Schedule of key inputs in valuation of embedded conversion features) (Details) (Recurring basis [Member], Derivative instruments related to embedded conversion features [Member], Level 3 [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield
Exercise price (in dollars per share)	$ 3.00
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate (as a percent)	0.43%
Volatility (as a percent)	146.00%
Expected life in years	1 year 11 months 16 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate (as a percent)	0.58%
Volatility (as a percent)	157.00%
Expected life in years	2 years 1 month 2 days

XML

PREPAID EXPENSES AND OTHER ASSETS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
PREPAID EXPENSES AND OTHER ASSETS [Abstract]
Prepaid investor relations services	$ 162,000
Prepaid accounting fees	550
Interest receivable	25,900
Total prepaid expenses and other assets	$ 188,450

XML

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities:
Net loss	$ (1,339,858)	$ (18,227)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation - assets of discontinued operations		20,299
Loss on sale of assets of discontinued operations	15,704
Management fees and reimbursement of expenses, related parties, net, of discontinued operations		(38,389)
Amortization of debt discount	89,152
Non-cash interest expense	11,609
Convertible note payable issued for debt issuance costs	32,500
Loss on origination of derivative liability	12,810
Shares issued for services	34,000
Value of non-marketable equity securities recognized as revenue	(75,000)
Loss on revaluation of derivative liability	1,942
Changes in operating assets and liabilities:
Accounts receivable	(16,113)
Interest receivable	(13,150)
Due from related party	10,774
Inventory		(3,026)
Due to related party		5,445
Prepaid expenses	(26,450)
Accounts payable and accrued expenses	169,023	10,838
Net cash provided by (used in) operating activities	(1,093,057)	(23,060)
Investing activities:
Equity method investments	(50,000)
Equipment purchases related to discontinued operations		(18,215)
Net cash provided by (used in) investing activities	(50,000)	(18,215)
Financing activities:
Net proceeds from issuance of convertible debt and warrants	225,000
Proceeds from issuance of note payable	175,000
Repayment of notes payable, related party		(50,000)
Proceeds from convertible note payable, related party		50,000
Proceeds from issuance of common shares	900,000
Net cash provided by (used in) financing activities	1,300,000
Net increase (decrease) in cash	156,943	(41,275)
Cash, beginning of period	32,414	76,445
Cash, end of period	189,357	35,170
Supplemental schedule of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Investment in non-marketable equity securities received as consideration for deferred services	893,750
Investment in equity method investments received as consideration for deferred services	144,000
Investment in equity method investments received for commitment to issue common stock	88,000
Issuance of common stock for prepaid professional fees	162,000
Acquisition of notes receivable funded by convertible note payable	1,250,000
Issuance of convertible note payable for debt issuance costs	32,500
Warrants issued for debt discount	694,525
Debt conversion feature issued for debt discount	151,937
Debt conversion feature issued for interest payable discount	11,609
Conversion of note payable, related party, into common stock	$ 50,000

XML

PREPAID EXPENSES AND OTHER ASSETS

9 Months Ended

Sep. 30, 2014

PREPAID EXPENSES AND OTHER ASSETS [Abstract]

PREPAID EXPENSES AND OTHER ASSETS

NOTE 5 – PREPAID EXPENSES AND OTHER ASSETS

 Prepaid expenses and other assets consist of:

	September 30,2014		December 31, 2013
Prepaid investor relations services	$	162,000		$	—
Prepaid accounting fees		550			—
Interest receivable		25,900			—
	$	188,450		$	—

XML

DISCONTINUED OPERATIONS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Dec. 31, 2013
DISCONTINUED OPERATIONS [Abstract]
Amount of payable owed to former officer and director, exchanged for assets sold					$ 15,000
Revenues		32,278	20,684	91,144
Operating expenses:
Selling, general and administrative		30,870	63,872	56,601
Depreciation		6,986		20,299
Loss on disposal of assets			15,704
Total operating expenses		37,856	79,576	76,900
Income (loss) from discontinued operations, before income taxes		(5,578)	(58,892)	14,244
Provision for income taxes
Income (loss) from discontinued operations, net of income taxes		(5,578)	(58,892)	14,244
Equipment						$ 17,616

XML

EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2014

EQUIPMENT [Abstract]

Schedule of Equipment

Our equipment consists of the following at:

	September 30,2014		December 31, 2013
Equipment	$	—		$	131,584
Less accumulated depreciation		—			(113,968	)
	$	—		$	17,616

XML

GOING CONCERN (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
GOING CONCERN [Abstract]
Net loss (income)	$ 706,638	$ 27,272	$ 1,339,858	$ 18,227
Net cash used in operating activities			1,093,057	23,060
Working capital deficit	306,674		306,674
Accumulated deficit	$ 1,496,461		$ 1,496,461		$ 156,603

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 15 –COMMITMENTS AND CONTINGENCIES

Contractual Obligations and Commercial Commitments

On May 6, 2014, we entered into a consultancy agreement with two third party doctors that has a nine month term which can be renewed and/or extended by mutual agreement.  The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the three and nine months ended September 30, 2014, we have recognized $100,000 and $150,000 of the $200,000 cash payment obligations as research and development expenses in our condensed statements of operations. At September 30, 2014, $100,000 is included in accrued expenses on our condensed balance sheet. The value of the 100,000 shares will be recognized upon achievement of the goals, currently anticipated to be during the fourth quarter of 2014.

Legal Proceedings

We were not subject to any legal proceedings during the three and nine months ended September 30, 2014, and, to the best of our knowledge, no legal proceedings are pending or threatened.